Rational Vaccines Announces a Clinical Study of the Frequency of Symptomatic Herpes Simplex Type 1 and 2 (HSV-1 and HSV-2) Virus in HIV Patients

WOBURN, Mass. and OXFORD, England: WOBURN, Mass. and OXFORD, England, Dec. 14, 2021 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced the launch of a clinical trial designed to investigate the disease burden of herpes simplex virus...

Click to view original post